Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers

被引:106
作者
Mendell, Jeanne [1 ]
Tachibana, Masaya [2 ]
Shi, Minggao [1 ]
Kunitada, Satoshi [2 ]
机构
[1] Daiichi Sankyo Pharma Dev, Edison, NJ 08837 USA
[2] Daiichi Sankyo Co Ltd, Tokyo, Japan
关键词
edoxaban; DU-176b; food effect; factor Xa inhibitor; pharmacokinetics; WARFARIN; DU-176B;
D O I
10.1177/0091270010370974
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
The primary objective of this study was to assess the effect of a standard high-fat meal on the single-dose (60 mg) pharmacokinetics (PK) of edoxaban in healthy Japanese and Caucasian male volunteers matched by body mass index. This was an open-label, randomized, 2-period crossover study. All 32 enrolled volunteers completed the study per protocol. Both serial blood and urine samples were collected, and edoxaban concentrations were analyzed by a validated liquid chromatography/tandem mass spectrometry method. Activated partial thromboplastin and prothrombin times were obtained as measures of pharmacodynamic effect. The point estimates of the geometric mean ratios (fed/fasted) for AUC(0-t), AUC(0-8), and C-max demonstrated modest increases ranging from 6% to 22% across PK parameters for both race cohorts. The disposition was similar in both Japanese and Caucasian matched volunteers with slightly higher AUC values (ranging from 7%-9%) in Caucasians. There were no serious adverse events during the study. All drug-related adverse events were mild and self-limited, and none were bleeding related. Both Japanese and Caucasian volunteers demonstrated a modest but clinically insignificant food effect. It was concluded that edoxaban can be administered without regard to food.
引用
收藏
页码:687 / 694
页数:8
相关论文
共 12 条
[1]
[Anonymous], 2002, GUID IND FOOD EFF BI
[2]
Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran [J].
Ezekowitz, Michael D. ;
Connolly, Stuart ;
Parekh, Amit ;
Reilly, Paul A. ;
Varrone, Jeanne ;
Wang, Susan ;
Oldgren, Jonas ;
Themeles, Ellison ;
Wallentin, Lars ;
Yusuf, Salim .
AMERICAN HEART JOURNAL, 2009, 157 (05) :805-810
[3]
Fuji T, 2008, BLOOD, V112, P19
[4]
DU-176b, a potent and orally active factor Xa inhibitor:: in vitro and in vivo pharmacological profiles [J].
Furugohri, T. ;
Isobe, K. ;
Honda, Y. ;
Kamisato-Matsumoto, C. ;
Sugiyama, N. ;
Nagahara, T. ;
Morishima, Y. ;
Shibano, T. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (09) :1542-1549
[5]
Giugliano R, 2009, J THROMB HAEMOST, V7, P200
[6]
Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (Rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects [J].
Kubitza, D ;
Becka, M ;
Zuehlsdorf, M ;
Mueck, W .
JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (05) :549-558
[7]
Mendell J, 2009, J CLIN PHARMACOL, V49, P1122
[8]
Warfarin and its interactions with foods, herbs and other dietary supplements [J].
Nutescu, Edith A. ;
Shapiro, Nancy L. ;
Ibrahim, Sonia ;
West, Patricia .
EXPERT OPINION ON DRUG SAFETY, 2006, 5 (03) :433-451
[9]
OGATA K, 2010, J CLIN PHARM 0115
[10]
Raskob G, 2008, EUR HEART J, V29, P609